TCGA-44-2659-01A-01R-0946-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.310
- KRAS_SIGNALING_UP+0.260
- BILE_ACID_METABOLISM+0.230
- INTERFERON_ALPHA_RESPONSE+0.220
- INTERFERON_GAMMA_RESPONSE+0.210
- COAGULATION+0.200
- UV_RESPONSE_DN+0.200
- PANCREAS_BETA_CELLS+0.190
- INFLAMMATORY_RESPONSE+0.160
- KRAS_SIGNALING_DN+0.160
Top 10 suppressed
- E2F_TARGETS-0.650
- MYC_TARGETS_V1-0.590
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V2-0.560
- OXIDATIVE_PHOSPHORYLATION-0.520
- DNA_REPAIR-0.450
- MITOTIC_SPINDLE-0.440
- MTORC1_SIGNALING-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- CHOLESTEROL_HOMEOSTASIS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG47 | — | — | 0.913 |
| 2 | TCGA-44-6147-01A-11R-1755-07 | — | cohortA1 | 0.911 |
| 3 | TCGA-55-7816-01A-11R-2170-07 | — | cohortMD2 | 0.911 |
| 4 | TCGA-75-7025-01A-12R-1949-07 | — | cohortA1 | 0.908 |
| 5 | ERR2278882 | — | — | 0.892 |
| 6 | TCGA-97-A4M5-01A-11R-A24X-07 | — | cohortA1 | 0.884 |
| 7 | C3L-03268 | — | cohortA1 | 0.882 |
| 8 | TCGA-97-A4M7-01A-11R-A24X-07 | — | cohortA1 | 0.882 |
| 9 | 20040019.LumA | — | A | 0.879 |
| 10 | C3N-03038 | — | cohortA1 | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| COMPLEMENT | 0.040 | Inavolisib | — uncovered |